NAD+ for Cellular Energy and Healthy Aging — Aging
NAD+ supplementation protocol to support mitochondrial function, cellular energy production, and healthy aging.
Overview
NAD+ (Nicotinamide Adenine Dinucleotide) is a critical coenzyme involved in cellular energy metabolism, DNA repair, and sirtuin activation. Levels decline with age, contributing to mitochondrial dysfunction. Recent 2024-2025 RCTs demonstrate NMN and NR supplementation safely elevate blood NAD+ levels with emerging evidence for functional benefits including improved muscle insulin sensitivity, enhanced aerobic capacity, better oxygen-carrying capacity, and walking performance in vascular disease.
Indications
- Age-related decline in cellular energy and mitochondrial function
- Support for healthy aging optimization
- Enhancement of metabolic health and NAD+ biosynthesis
- Cognitive function support and neuroprotection
Mechanism of Action
NAD+ levels decrease with age, leading to mitochondrial dysfunction and reduced cellular energy production
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Nicotinamide Mononucleotide | 250-500 mg | Once daily | Best studied oral precursor, 2024-2025 RCTs show safety and NAD+ elevation |
| Nicotinamide Mononucleotide | 600-900 mg | Once daily | Higher doses from multicenter RCTs, dose-dependent NAD+ increases |
| Nicotinamide Riboside | 300-600 mg | Once daily | Alternative oral precursor, RCT evidence for PAD and cognitive benefits |
| Nicotinamide Riboside | 1000 mg | Once daily | Dose from MCI cognitive trial, well-tolerated in older adults |
| NAD+ | 50 mg | Once daily | Start dose for first 2 weeks, convenient delivery |
| NAD+ | 75-100 mg | 1-2 times daily | Maintenance dose, rapid absorption, good bioavailability |
| NAD+ | 50-75 mg | 2-3 times weekly | Higher bioavailability, longer duration effects |
| NAD+ | 100-150 mg | 3-4 times weekly | Maximum therapeutic benefit, for experienced users |
| NAD+ | 250-500 mg | 1-2 times monthly | Highest bioavailability, clinical supervision required |
Evidence Grade
GRADE B
Safety & Contraindications
- Generally well-tolerated across all routes (oral, nasal, SC, IV) based on 2024-2025 RCT data
- May cause mild flushing or nausea, especially with IV infusions
- Oral NMN/NR doses up to 900-1000mg daily show good safety profiles in clinical trials
- Consult healthcare provider if pregnant, nursing, or on medications
- Use sterile technique for injectable formulations
- Some metabolic effects (e.g., insulin sensitivity) tissue-specific; general metabolic markers may not change